Antibody Drugs: Technologies and Global Markets
February 06, 2012
Wellesley, Mass. – According to a new technical market research report, ANTIBODY DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (BIO016H) from BCC Research (www.bccresearch.com), the global market for antibodies was valued at nearly $44.7 billion in 2011 and is expected to increase to $57.7 billion in 2016, a five-year compound annual growth rate (CAGR) of 5.3%.
The global market for antibodies can be separated into the U.S. and the rest of the world.
The U.S., worth $20.1 billion in 2011, is expected to increase at a CAGR of 6.4% to reach $27.4 billion in 2016.
The rest of the world, worth $24.5 billion in 2011, should reach $30.3 billion in 2016, a CAGR of 4.3%.
An antibody is a special kind of blood protein synthesized in lymphoid tissue in response to the presence of a specific protein. Antibodies circulate in the plasma to attack these specific proteins, called antigens, which are found on the surface of foreign cells. The antibody attacks the antigen and renders it harmless. To successfully recognize and protect the body from foreign substances, millions of antibodies are created, each one having the ability to target a unique antigen.
Therapeutic monoclonal antibodies (mAbs) represent the largest and one of the fastest-growing classes of biopharmaceutical products by sales in the U.S. and throughout the world. Of the top 20 drugs by sales throughout the world today, five are mAbs.
Globally, there are more than 300 mAb products in clinical-stage development by more than 100 companies for the treatment of virtually every debilitating disease. Hundreds more therapeutic mAbs are in earlier preclinical and discovery stages of development as well.
This study will be of interest to those working in the biotechnology and pharmaceutical industries and related life science, drug discovery, and diagnostic test manufacturing companies, as well as all those interested or actively working in drug research.
Antibody Drugs: Technologies and Global Markets( BIO016H )
Publish Date: Feb 2012
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand
- Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030 as Digital Health Infrastructure Reshapes Drug Development
Reports from Cell Biology
Recent News
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Long-Term Care and Home Healthcare Technology Market to Reach $64.8 Billion by 2030 as Aging Demographics and Remote Monitoring Reshape Care Delivery
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum